What is in the Product and How to Measure It?
DOI:
https://doi.org/10.21423/JRS-V04N03PIAbstract
Label claim, as its name implies, assures consumers that the claims printed on the label of a regulated product accurately represent the product within. Ruth et al. reports in “Consistency of label claims of internet-purchased hemp oil and cannabis products as determined using IMS and LC-MS: a market survey” of a qualitative and quantitative study of 23 hemp oil products using two advanced instrument methods: an ion mobility mass spectrometry method and a liquid chromatography high-resolution mass spectrometry method. Cannabis products have become a hotly debated topic due to recent legislative changes. Although several cannabinoid compounds are designated as Schedule I controlled substances by the U.S. Drug Enforcement Administration (USDEA), many state legislatures have legalized marijuana for medical use, recreational use, or both. Schedule I controlled substances are defined by DEA as “drugs with no currently accepted medical use and a high potential for abuse. Schedule I drugs are the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence” (USDEA). Regardless of state-level legislation and on-going debate in state legislature, science-driven research forms the background needed by the general public, public health officials, and policy makers to make informed decisions about cannabis products and marijuana. Particularly important from a public health perspective are methods to assess cannabis product content and safety. Ruth et al. found that some commercial products were not consistent with the label claim, foreshadowing future regulatory challenges of the cannabis industry, such as denoting compounds to be sought in testing, testing methods, and the implementation of quality control and quality assurance.
https://doi.org/10.21423/jrs-v04n03pi (DOI assigned 5/31/2019)
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
By submitting content to the Journal of Regulatory Science (JRS), authors agree to the following terms:
- Authors retain copyright and grant the JRS the right of first publication. Authors retain patent, trademark, and other intellectual property rights (including research data) and grant third parties the right to use, reproduce, and share the article according to the Creative Commons — Attribution-NonCommercial 4.0 International — CC BY-NC 4.0 license agreement. The JRS is an open access journal and, as a result, articles are free to use with proper acknowledgment of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process.
- If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article.
- The publication of the submission has been approved by all co-authors and responsible authorities at the institute or organization where the work has been carried out.
- Copyright has not been breached in seeking publication of the submission.